Brentuximab vedotin in the treatment of CD30+ PTCL | Blood | American Society of Hematology
You do not currently have access to this content.
Related Articles
Sex, lies, and iron deficiency: a call to change ferritin reference ranges
Abstract. Iron deficiency is a very common and treatable disorder. Of all the tests available to diagnose iron deficiency, the serum ferritin is the most…
Deep Dive: Matthew Ulrickson, MD | ASH Clinical News | American Society of Hematology
Khylia Marshall is a freelance journalist based in Tucson, Arizona. Dr. Ulrickson is section chief of hematology at Banner MD Anderson Cancer Center in Gilbert,…
Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Gustave Roussy, Université Paris-Saclay, Département…
Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis
Key PointsADAMTS13 exome/genome data from 807 162 gnomAD population was analyzed to establish worldwide/within-population prevalence of hereditary TTP.Here
Clinical Research Training in Hematology
The CRTH 2025 call for application will open April 2, 2024.What is Clinical Research Training in Hematology (CRTH)?[image src=”/assets/CRTH-logo-white-space.png” id=”6915″ width=”183″ height=”59″ class=”right ss-htmleditorfield-file image”]Clinical…
Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy
Key Points. +1q is associated with worse hematologic response rate and event-free survival with daratumumab-based frontline therapy in AL amyloidosist(11;1
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Key Points. With longer follow-up, significantly longer median PFS was maintained with ide-cel vs standard regimens (SRs); safety remained consistentOS ana
HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation
Key PointsThis trial used a class I–restricted TCR and a CD8 coreceptor to enable antigen–specific CD8+ and CD4+ T-cell function.Primary end points of feas
How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients
Organizing pneumonia (OP) after allogeneic hematopoietic stem cell transplant (HCT OP) is a major cause of severe morbidity and mortality and is usually as
As a Professor of Medicine, I’m Proud to Say I’m Still Here | ASH Clinical News | American Society of Hematology
Brea C. Lipe, MD, is a professor of medicine and clinical director of the multiple myeloma program at the James P. Wilmot Cancer Center of…
